181 related articles for article (PubMed ID: 18613407)
1. State of the iron metabolism in patients with chronic hepatitis C type C does not influence antiviral treatment with interferon and ribavirin.
Jurczyk K; Karpińska E; Wawrzynowicz-Syczewska M; Morańska I; Noceń I; Chlubek D; Boroń-Kaczmarska A
Hepatogastroenterology; 2008; 55(82-83):557-61. PubMed ID: 18613407
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of chronic hepatitis C treatment in hemophilic patients.
Husa P; Roznovsky L; Smejkal P; Husova L; Penka M; Dite P
Hepatogastroenterology; 2005; 52(65):1541-4. PubMed ID: 16201114
[TBL] [Abstract][Full Text] [Related]
3. Interferon-alpha plus ribavirin combination therapy for the treatment of chronic hepatitis C in interferon non-responders.
Hasan F; Asker H; al Shamali M; al Kalaoui M; al Nakib B
Hepatogastroenterology; 2000; 47(36):1642-4. PubMed ID: 11149023
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy of combination therapy with interferon-alpha and ribavirin for chronic hepatitis C in relation to liver fibrosis and serum aminotransferase activity].
Karpińska E; Wawrzynowicz-Syczewska M; Jurczyk K; Morańska I; Urbanowicz W; Boroń-Kaczmarska A
Wiad Lek; 2005; 58(11-12):616-21. PubMed ID: 16594470
[TBL] [Abstract][Full Text] [Related]
5. Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C.
Hofer H; Osterreicher C; Jessner W; Penz M; Steindl-Munda P; Wrba F; Ferenci P
J Hepatol; 2004 Jun; 40(6):1018-22. PubMed ID: 15158344
[TBL] [Abstract][Full Text] [Related]
6. [Serologic response against hepatitis C virus as a predictive factor to the treatment with interferon].
Garrido A; Lepe JA; Guerrero FJ; Palomo S
Enferm Infecc Microbiol Clin; 2000 Dec; 18(10):512-5. PubMed ID: 11198002
[TBL] [Abstract][Full Text] [Related]
7. Hepatic iron overload does not prevent a sustained virological response to interferon-alpha therapy: a long term follow-up study in hepatitis C-infected patients with beta thalassemia major.
Sievert W; Pianko S; Warner S; Bowden S; Simpson I; Bowden D; Locarnini S
Am J Gastroenterol; 2002 Apr; 97(4):982-7. PubMed ID: 12003436
[TBL] [Abstract][Full Text] [Related]
8. The effect of interferon alpha plus ribavirin on health-related quality of life in chronic C hepatitis. The Romanian experience.
Pojoga C; Dumitraşcu DL; Pascu O; Grigorescu M
J Gastrointestin Liver Dis; 2006 Mar; 15(1):31-5. PubMed ID: 16680230
[TBL] [Abstract][Full Text] [Related]
9. Treatment of chronic hepatitis C with amantadine hydrochloride in patients who had not responded to previous treatment with interferon-alpha and/or ribavirin.
Di Martino V; Boudjema H; Delacour T; Cazier A; Caron C; Coutarel P; Dumouchel P; Cadranel JF
Clin Infect Dis; 2001 Mar; 32(5):830-1. PubMed ID: 11229855
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of organ- and non-organ-specific autoantibodies on the response to anti-viral treatment of patients with chronic hepatitis C.
Gatselis NK; Georgiadou SP; Koukoulis GK; Tassopoulos N; Zachou K; Liaskos C; Hatzakis A; Dalekos GN
Aliment Pharmacol Ther; 2006 Dec; 24(11-12):1563-73. PubMed ID: 17094775
[TBL] [Abstract][Full Text] [Related]
11. Liver fibrosis and hepatic stellate cells improvement of chronic hepatitis C patients by interferon-beta-1a with or without sustained viral response.
Rao HY; Wei L; Li J; Zhang LF; Chen HY; Zhu LM; Liu F; Sun Y; Wang H
Hepatogastroenterology; 2009; 56(90):328-34. PubMed ID: 19579592
[TBL] [Abstract][Full Text] [Related]
12. [Serum iron parameters in chronic hepatitis C patients and comparison of the results before and during antiviral treatment].
Bolewska B; Wojtacha A; Juszczyk J; Przedwojewski M
Pol Merkur Lekarski; 2005 May; 18(107):552-5. PubMed ID: 16161954
[TBL] [Abstract][Full Text] [Related]
13. Assessment of iron metabolism in children with chronic hepatitis B -- prognostic factor in interferon alpha therapy.
Chrobot A; Chrobot AM; Szaflarska-Szczepanik A
Med Sci Monit; 2002 Apr; 8(4):CR269-73. PubMed ID: 11951069
[TBL] [Abstract][Full Text] [Related]
14. Changes in serum lipid concentrations in patients with chronic hepatitis C virus positive hepatitis responsive or non-responsive to interferon therapy.
Hamamoto S; Uchida Y; Wada T; Moritani M; Sato S; Hamamoto N; Ishihara S; Watanabe M; Kinoshita Y
J Gastroenterol Hepatol; 2005 Feb; 20(2):204-8. PubMed ID: 15683422
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin.
Trocme C; Leroy V; Sturm N; Hilleret MN; Bottari S; Morel F; Zarski JP
J Viral Hepat; 2006 Oct; 13(10):643-51. PubMed ID: 16970595
[TBL] [Abstract][Full Text] [Related]
16. Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1,386-patient study from Taiwan.
Huang JF; Yu ML; Lee CM; Dai CY; Hou NJ; Hsieh MY; Wang JH; Lu SN; Sheen IS; Lin SM; Chuang WL; Liaw YF
Aliment Pharmacol Ther; 2007 May; 25(9):1029-37. PubMed ID: 17439503
[TBL] [Abstract][Full Text] [Related]
17. Development of thyroid diseases in the treatment of chronic hepatitis C with alpha-interferon may be a good prognosticator in achieving a sustained virological response: a meta-analysis.
Tran HA; Malcolm Reeves GE; Gibson R; Attia JR
J Gastroenterol Hepatol; 2009 Jul; 24(7):1163-8. PubMed ID: 19682190
[TBL] [Abstract][Full Text] [Related]
18. Response of chronic hepatitis C to interferon-alpha treatment and relationship with iron metabolism.
Martín-Vivaldi R; Nogueras F; González A; Quintero D; Pinel LM; Castro T; Hernández A
Rev Esp Enferm Dig; 1997 Jul; 89(7):523-30. PubMed ID: 9265838
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of chronic hepatitis C with interferon alpha and ribavirin. Results in "real life"].
Pariente A; Djilloul A; Cadranel JF;
Gastroenterol Clin Biol; 2003 Jun; 27(6-7):590-5. PubMed ID: 12910222
[TBL] [Abstract][Full Text] [Related]
20. [Serum levels of vascular endothelial growth factor in chronic hepatitis C patients treated with interferon alpha and ribavirin].
Janczewska-Kazek E; Marek B; Pisula A; Kajdaniuk D; Witor A; Magiera M; Witor A
Wiad Lek; 2007; 60(3-4):120-3. PubMed ID: 17726862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
